Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China
Due to lower BM CIR, lorlatinib showed higher BM management cost savings compared to crizotinib and alectinib in Chinese 1 L patients.
Authors
- N. Rifi (ORCID: https://orcid.org/0009-0004-7627-9519)
- Luan Luan (ORCID: https://orcid.org/0000-0002-2173-2177)
- Hongchao Li (ORCID: https://orcid.org/0000-0001-5151-9724)
- Hannah Le
- Jing Xue
- Fanfan Zhu
- Dingsiman Li
- Peng Dong
- Jia Duan
- Bingqi Hu
Institutions
- China Pharmaceutical University (CN)
- Pfizer (United States) (US)
- Pharmacoeconomics and Health Outcomes Research Iberia (Spain) (ES)
Publication Details
- Journal
- Lung Cancer Management
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1080/17581966.2026.2622902
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00